Beth Keshishian

Media & Comms Strategist, Public Health Advocate, Animal Lover, Food & Wine Enthusiast, Globetrotter; opinions are my own

[Beth Keshishian @NYCBeth]

Ophthalmology is experiencing rapid advances in innovation, attracting substantial investment. Join me at #BIO2025 for a panel to discuss:

Improving and Restoring Vision in Blinding Eye Diseases

Tuesday, June 17 | 1:45-2:45 PM ET | Room 254B
More here: https://t.co/DhOB4GUGev

[Strand Therapeutics @StrandTx]

Come by our poster today at #AACR25 to learn about the groundbreaking data from the preclinical program for STX-003 - a systemically delivered self-replicating mRNA encoding IL-12.

Session Details:
Date and Time: April 28, 2:00-5:00 pm CT
Location: Section 37

[Beth Keshishian @NYCBeth]

Big week for @AurionBiotech! Thank you @lisa_stiffler and @geekwire for sharing the exciting news that Aurion received #FDA BTD and RMAT designations for their novel, cell therapy and that CEO Greg Kunst @gdk62 was named @EY_US Entrepreneur of the Year #EOYMTNWEST! More here:

[GeekWire @geekwire]

Aurion Biotech gets FDA approval to speed development of vision restoring treatment https://t.co/HUUkz0XN96

[Beth Keshishian @NYCBeth]

Congratulations to the team @StrandTx for bringing pioneering programmable #mRNA technology, STX-001, for #cancer from the lab to the clinic!

[Strand Therapeutics @StrandTx]

Breaking News: Today Strand announced the first patient was treated with STX-001, a programmable mRNA therapy, in a Phase 1 trial of cancer patients with solid tumors. Read more: https://t.co/PPsHJ5amY4

#FirstPatientDosed #Oncology #ASCO24

[Beth Keshishian @NYCBeth]

@adamfeuerstein 1.21 gigawatts

[Beth Keshishian @NYCBeth]

@chrissyfarr Every time I go it feels like I’m entering a movie set or Downton Abbey.

[Beth Keshishian @NYCBeth]

Learn about the future of multiplex gene editing and programmable nucleases to cure HIV and other chronic viral infectious diseases in this interview with @ExcisionBio @NucleaseLab and @TMenichiello @_CellandGene

[TJ Cradick @NucleaseLab]

Thanks Tyler Menichiello @_CellandGene. Great to share exciting work at @ExcisionBio: advances in multiplex #GeneEditing & programmable nucleases moving us towards a cure for #HIV and other chronic, viral infectious diseases  - #HSV, #HBV and PLM/JCV.
https://t.co/gtLgW0YgEv

[Ron Leuty @rleuty_biotech]

An #HIV cure? @ExcisionBio inches closer to goal with FDA designation https://t.co/4bgzAOq2Jh via @SFBusinessTimes

[Beth Keshishian @NYCBeth]

@AndrewE_Dunn Congratulations, they’re lucky to have you!

[BioWorld @BioWorld]

.@AurionBiotech victorious with Vyznova cell therapy approval in Japan https://t.co/ebgDjyhfWj #biotech #pharma

[Beth Keshishian @NYCBeth]

@CityMD sent me a bill for $270.00 on Aug. 2022 for a COVID test I took in Nov. 2020. #CityMD submitted a $300.00 insurance claim for the visit and $0 for the test. I'm one of many to get this type of bill. Is this correct? Is it legal? @survivorcorp @NewYorkStateAGO

[Adaptive Biotech @AdaptiveBiotech]

“But where antibodies stumble, killer Ts shine.”

Get to know the elite fighting forces of your immune system in the latest by @KatherineJWu of @TheAtlantic.
https://t.co/KGtafoxT9W

[Harlan Robins @HarlanRobins]

Preliminary data using @AdaptiveBiotech's immune medicine platform finds that greater than two thirds of the T-cell response to vaccines is on target against the #Omicron variant. New manuscript available here: https://t.co/95Ff0NB6c7

(1/6)

[Mike Pellini, MD @MichaelPellini]

Public health officials are making decisions about COVID-19 vaccinations with incomplete information about immunity. @dramyabernethy and I wrote an op-ed for @morningconsult with recommendations on the path forward.
https://t.co/tJcBs2wo1Q

[Christina Farr @chrissyfarr]

I said it on stage with @Jonathan_Bush & @GlenTullman & will share it again: Great storytellers have had outsized success in digital health.

A skillset that should not be underestimated.

[Eric Topol @EricTopol]

Just published @NEJM
Neutralizing antibody levels and T cells response out to 8 months for Pfizer, Moderna and J&J vaccines
https://t.co/ghAgk3Y4kR
Moderna highest antibody response; J&J while lower doesn't fall off and best CD8 T-cell response at 8 months

[Adaptive Biotech @AdaptiveBiotech]

Join us at @DPC_Summit on July 20 at 9 a.m. EDT for a special keynote panel on COVID-19 and the road ahead featuring CSO Harlan Robins and leaders from @WHO, @CDC, @Pfizer and more.

Register at https://t.co/Zj6LC9xoq9.

#DPCSummit #NoMorePandemics

[Adaptive Biotech @AdaptiveBiotech]

The new Resilience series from our partners @Microsoft explores the role of science and technology in addressing the pandemic & other crises to emerge more resilient into the future. Featuring Adaptive’s @RachelGittelman. https://t.co/UczeETzK6z #SocietalResilience

[Beth Keshishian @NYCBeth]

Listen to our COO Mark Adams talk to @statnews @rickberke about T cells and how they could help transform medicine!

[Adaptive Biotech @AdaptiveBiotech]

Join COO Mark Adams at @STATnews Health Tech Summit on Tues. 5/11 at 3:35pm ET as he discusses how understanding T cells could change medicine and the way we diagnose and treat many different diseases. Moderated by @RickBerke. Register: https://t.co/tDYBAKpMdz

[Beth Keshishian @NYCBeth]

Awesome to be honored by @FastCompany as part of their 2021 World Changing Ideas award! #FCWorldChangingIdeas #BeAdaptive #Got2Adapt

[Adaptive Biotech @AdaptiveBiotech]

We’re honored to announce that T-Detect COVID has been recognized as a finalist in @FastCompany’s 2021 World Changing Ideas Awards with our partners @Microsoft. https://t.co/cWTjb0YY3v

#FCWorldChangingIdeas